Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer's Disease 100%
• Neurologic Disease 100%
• Brexanolone 100%
• Disease 18%
• Amyloid 18%
• Mouse 9%
• Long Term Exposure 9%
• Combination Therapy 9%
• Chronic Disease 9%
• Genetic Risk 9%
• Mouse Model 9%
• Epileptic State 9%
• Multiple Sclerosis 9%
• Route of Administration 9%
• Diabetic Neuropathy 9%
• Traumatic Brain Injury 9%
• Disease Model 9%
• Neurosteroid 9%

Neuroscience

• Alzheimer's Disease 100%
• Neurological Disorder 100%
• Allopregnanolone 100%
• Amyloid 18%
• Promoter Region 9%
• Gene Expression 9%
• Cell Signaling 9%
• Neurotrauma 9%
• Traumatic Brain Injury 9%
• Nervous System Disorder 9%
• Status Epilepticus 9%
• Multiple Sclerosis 9%
• Neural Stem Cell 9%
• Neurogenesis 9%
• Diabetic Neuropathy 9%
• Neurosteroid 9%

Keyphrases

• Niemann-Pick 9%
• Genetic Burden 9%
• Therapeutic Translation 9%